 WARMER, Pa., Sept. 21, 2021 GLOBE NEWSWIRE -- Arbutus Biopharma Corporation Nasdaq: ABUS, a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus HBV infection, as well as therapies to treat coronaviruses including COVID-19, today announced the Company has appointed Lisa M. Caperelli to the newly created position of Vice President of Investor Relations, leading investor relations strategy and communications activities, reporting to David Hastings, Arbutus Chief Financial Officer. 